Klatskin tumor treated by inter-disciplinary therapies including stereotactic radiotherapy: A case report

Gerhild Becker, Felix Momm, Henning Schwacha, Norbert Hodapp, Henning Usadel, Michael Geißler, Annette Barke, Annette Schmitt-Gräff, Karl Henne, Hubert E. Blum

**Abstract**

In view of the poor prognosis of patients with cholangiocarcinoma (CCC), there is a need for new therapeutic strategies. Inter-disciplinary therapy seems to be most promising. Radiotherapy is an effective alternative to surgery for hilar CCC (Klatskin tumors) if an adequate radiation dose can be delivered to the liver hilus. Here, we describe a patient for whom we used a stereotactic radiotherapy technique in the context of an inter-disciplinary treatment concept. We report a 45-year-old patient with inoperable hilar CCC, who was treated using an inter-disciplinary concept including stereotactic radiotherapy. This highly precise technique also known as extracranial stereotactic radiotherapy, was first developed for the treatment of brain tumors. Using a body frame, it is applicable to the whole body. By this technique, an adequate radiation dose can be delivered to the tumor, while sparing normal structures in the liver hilus and the upper abdomen that are highly radiosensitive. A total dose of 48 Gy (3×4 Gy/wk) could be given and therapy is well tolerated. Although the tumor is locally advanced at the time of diagnosis and prognosis was extremely poor, an unusual long survival of more than 4 years with a good quality of life could be achieved. Stereotactic radiotherapy seems to be a promising choice of treatment for hilar CCC.

**CASE REPORT**

In December 1998, a 45-year-old male patient was admitted to our hospital. The only pathologic finding at clinical examination was a generalized, painless jaundice. The patient reported itching, but no abdominal pain, no fever, and no weight loss. Laboratory tests showed elevated levels of alkaline phosphatase (591 U/L; normal 35-104 U/L), γ-glutamyltransferase (75 U/L; normal <39 U/L) and bilirubin (22.8 mg/dL; normal <1.2 mg/dL). C-reactive protein increased slightly (15 mg/L; normal <5 mg/L). The tumor antigen CA 19-9 was elevated (405 U/L; normal <37 U/L). All other routine biochemical tests were normal. Abdominal ultrasound examination showed dilation of intra-hepatic and extra-hepatic bile ducts. Computer

**INTRODUCTION**

Cholangiocarcinoma (CCC) is the second most common primary liver cancer after hepatocellular carcinoma[1]. Its prognosis is poor. The 5-year survival after surgical treatment with curative intention is 10-30%[2,3], but at the time of diagnosis less than one-third of tumors are resectable[4]. Single agent or combination chemotherapy and conventional radiation therapy are so far not effective, neither as primary treatment nor as adjuvant treatment after resection[1,3]. The majority of patients survive less than 12 mo after diagnosis[5,6]. Thus, there is a strong need for new therapeutic strategies. Here we report a 45-year-old patient with inoperable hilar CCC, who was treated using an inter-disciplinary concept including stereotactic radiotherapy. This highly precise technique also known as extracranial stereotactic radiotherapy[7], was first developed for the treatment of brain tumors. Using a body frame, it is applicable to the whole body. By this technique, an adequate radiation dose can be delivered to the tumor, while sparing normal structures in the liver hilus and the upper abdomen that are highly radiosensitive. A total dose of 48 Gy (3×4 Gy/wk) could be given and therapy is well tolerated. Although the tumor is locally advanced at the time of diagnosis and prognosis was extremely poor, an unusual long survival of more than 4 years with a good quality of life could be achieved. Stereotactic radiotherapy seems to be a promising choice of treatment for hilar CCC.
tomography (CT) and magnetic resonance imaging (MRI) revealed a 6 cm × 7 cm tumor in hepatic duct bifurcation and cholestasis predominantly in the atrophic left lobe of the liver. Several enlarged lymph nodes were detected in the hepato-duodenal ligament and one retro-pancreatic lymph node in contact to the inferior vena cava. Endoscopic retrograde cholangiopancreatography (ERCP) showed a stenosis of the hepatic duct bifurcation. A biopsy was taken and using percutaneous transhepatic cholangial drainage (PTCD), an external-internal Yamakawa drainage was placed. Histological examination revealed a highly differentiated CCC. Chest X-ray showed no evidence for metastases. Explorative laparotomy showed a non-resectable tumor. The tumor was classified as American Joint Committee on Cancer stage III according to the staging system for CCC\(^\text{9}\) and as type IV according to modified Bismuth-Corlette classification for hilar CCC\(^\text{9,10}\). The biliary drain was internalized post-operatively by implanting a metallic Memotherm stent (60 mm / 10 mm, Fa. Bard-Angiomed, Karsruhe, Germany). Subsequently a stereotactic radiotherapy with 48 Gy was performed for over 4 wk (3 × 4 Gy per wk) using the technique of Lax et al.\(^\text{7,11}\), with slight modifications.

After careful fixation of the patient in a body frame, treatment planning was performed in series of 45 axial CT slices with a distance and thickness of 5 mm. The planning target volume\(^\text{12,13}\), including the clinical target volume (tumor and involved structures/lymphatic nodes) at a distance between 3 and 5 mm to compensate for organ motion and repositioning errors, was 370 cm\(^3\). To check the repositioning accuracy in the body frame, a second CT series was performed few days after the first. The maximum positioning deviation in the region of the target volume was less than 3 mm. An optimal dose distribution could be achieved with seven coplanar conformal photon beams from a 6 MV linear accelerator (Figure 1). Using this technique, the mean dose values to liver, right kidney, spleen, and duodenum could be kept at 20.2, 3.2, 8.7, and 22.2 Gy, respectively. The patient developed cholangitis 2 mo after radiotherapy. An ERCP showed a stenosis close to the papilla Vateri. A biopsy was not conclusive and could not determine whether the stenosis was caused by tumor or radiation. The patient was treated with antibiotics. An internal plastic stent (10F / 7 cm, Endo-Flex GmbH, Voerde, Germany) was placed to relieve the distal biliary obstruction. Jaundice and associated symptoms resolved. The patient was followed up at 3-mo intervals. Because transhepatic biliary stents have a 1-year patency rate of only 50%\(^\text{14,15}\), the stent was replaced endoscopically every 3 mo between May 1999 and July 2003. MRI, in November 1999, showed no contrast medium enhancement in the tumor region and stable size of the lymph nodes. MRI, one year later (October 2000), showed constant size of the tumor, but a slightly contrast medium enhancement and enlargement of one retro-pancreatic lymph node consistent with a slowly growing residual tumor. In addition, a metastasis was detected in the right lobe of the liver. The patient refused chemotherapy. MRI, in April 2001, showed stable disease. In July 2001, the patient reported a weight loss of 18 kg in 2 mo and pain in the right chest. MRI revealed tumor progression and a metastasis in the right chest wall. Therefore, a combined palliative radiochemotherapy was initiated in September 2001. The chest wall metastasis was irradiated with a photon beam of a 6 MV linear accelerator with a total dose of 24 Gy (3 × 4 Gy / wk). Chemotherapy with gemcitabine 1 000 mg/m\(^2\) was initiated. MRI, after three cycles of chemotherapy in December 2001, showed partial remission with regression of all lesions. Therefore, chemotherapy was continued. Because of thrombocytopenia and anemia, only two additional cycles of gemcitabine at a reduced dose could be given and chemotherapy had to be stopped in March 2002. After tumor progression, the patient received four cycles of 5-fluorouracil/leucovorin/oxaliplatin FOLFOX\(^\text{17}\) and two cycles of 5-fluorouracil/leucovorin/irinotecan FOLFIRI. In July 2003, MRI showed significant progression of the tumor. Though the tumor had such a final progression, the patient had a good quality of life for more than 4 years. Four years and six months after diagnosis he died of liver failure.

The treatment course of the patient is shown in Figure 2.
benefit for patients receiving PDT that bilary stenting with and without PDT shows a survival benefit for patients receiving PDT[9]. In a small number of patients with unresectable CCC and failed endoscopic stents, photodynamic therapy (PDT) has been used. This technique involves the intravenous application of a photosensitizer followed by intra-luminal cholangioscopic photoactivation and generation of oxygen free radicals that harm cancer cells preferentially. Therapy decreases bilirubin levels and leads to a slightly better survival rate[2,2,2,3]. It was reported that biliary stenting with and without PDT shows a survival benefit for patients receiving PDT[9]. However, a puzzling aspect of the study is the failure to relieve biliary obstruction with stenting alone. Therefore the observed survival benefit is probably caused by relief of cholestasis rather than by a reduction of tumor and it remains unclear if PDT prolongs survival in patients responding to conventional biliary stenting procedures. Although this new technique appears promising, further studies are needed. Chemotherapy has not been shown to have a significant impact on survival[23]. The majority of reports use 5-FU alone or in combination with leucovorin, methotrexate, cisplatin, mitomycin C, or interferon alpha[9]. In some phase II studies, a response rate of about 20% is reported for gemcitabine[2,2,2,7]. The majority of reports concerning chemotherapy in patients with CCC are retrospective and include only few patients. In intra-hepatic CCC, transarterial chemoperfusion in combination with temporary embolization of the feeding artery can be performed. But randomized controlled trials demonstrating an impact on survival are lacking. Few studies have reported benefits of primary or adjuvant standard radiation therapy[2,2,9,29]. There are no randomized controlled trials demonstrating a therapeutic effect of brachytherapy or external beam radiotherapy[9]. The main problem of radiation therapy of the upper abdomen is to deliver an adequate dose to the tumor without serious side effects. Using a conforming, stereotactic radiation technique, a steep dose gradient can be obtained[9]. This means that a high radiation dose reaches the tumor while the normal tissue around the target volume is irradiated with comparatively low doses. Such a highly precise dose distribution is a need in radiotherapy of the liver hilus. Apart from the dose distribution the repositioning accuracy of the target volume is central to a successful radiation therapy. The high repositioning accuracy by a body frame can explain the differences between our patient and published cases with respect to side effects and tumor regression. Thus, stereotactic radiotherapy using a body frame is a valuable option for non-invasive treatment of inoperable tumors in critical regions as the liver hilus. Further technical developments as image guided radiotherapy or breath-triggered radiotherapy should further increase the repositioning accuracy and may make this technique available for routine use.

In conclusion, considering the generally poor prognosis of patients with Klatskin tumor, the long-term survival of our patient treated by stereotactic radiotherapy should encourage a systematic evaluation of this therapeutic strategy by prospective and randomized protocols.

REFERENCES

1 Martin R, Jarnagin W. Intrahepatic cholangiocarcinoma. Current management. Minerva Chir 2003; 58: 469-478
2 Klemppaunder, Ridder CJ, Werner M, Weimann A, Pichlmayr R. What constitutes long-term survival after surgery for hilar cholangiocarcinoma? Cancer 1997; 79: 26-34
3 Burke EC, Jarnagin WR, Hochwald SN, Pisters PW, Fong Y, Blumgart LH. Hilar cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system. Ann Surg 1998; 228: 385-394
4 Reding R, Board JL, Lebeau G, Launois B. Surgical management of 552 carcinomas of the bile duct (gall bladder and periampullary excluded). Ann Surg 1991; 213: 236-241
5 Anderson CD, Pinson CW, Berlin J, Char RS. Diagnosis and treatment of cholangiocarcinoma. Oncologist 2004; 9: 43-57
6 Chamberlain RS, Blumgart LH. Hilar cholangiocarcinoma: a review and commentary. Ann Surg Oncol 2000; 7: 55-66
7 Lax I, Blomgren H, Naslund I, Svensson R. Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. Acta Oncol 1994; 33: 677-683
8 American Joint Committee on Cancer, eds. AJCC Cancer Staging Manual. 5th ed. Philadelphia: Lippincott-Raven 1997
9 Bismuth H, Corlette MB. Intraepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver. Surg Gynecol Obstet 1975; 140: 170-178
10 Bismuth H, Nakache R, Diamond T. Management strategies in resection for hilar cholangiocarcinoma. Ann Surg 1992; 215: 31-38
11 Blomgren H, Lax I, Naslund I, Svensson R. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol 1995; 34: 861-870
12 ICRU Report No. 50: Prescribing, Recording and Reporting Photon Beam Therapy, 1993
13 ICRU Report No. 62: Prescribing, Recording and Reporting Photon Beam Therapy (Supplement to ICRU Report 50), 1999
14 Jayarajah DR, Klintmalm GB. Is liver transplantation indicated for cholangiocarcinoma? J Hepatobil Pancreat Surg 1998; 5: 48-51
15 Shapiro MJ. Management of malignant biliary obstruction: nonoperative and palliative techniques. Oncology 1995; 9: 493-496
16 Goldstein RM, Stone M, Tillery GW, Senzer N, Levy M, Husberg BS, Gonsa T, Klintmalm G. Is liver transplantation indicated for cholangiocarcinoma? Am J Surg 1993; 166: 768-771
17 Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation 2000; 69: 1633-1637
18 Thuluvath PJ, Rai R, Venbru AC, Yeo CJ. Cholangiocarcinoma: a review. Gastroenterologist 1997; 5: 306-315
19 Davids PH, Groen AK, Rauws EA, Tytgat GN, Huibregtse K. Randomised trial of self-expanding metal stents versus
polyethylene stents for distal malignant biliary obstruction. Lancet 1992; 340: 1488-1492

20 Kaassis M, Boyer J, Dumas R, Ponchon T, Coumaros D, Delcenserie R, Canard JM, Fritsch J, Rey JF, Burtin P. Plastic or metal stents for malignant stricture of the common bile duct? Results of a randomized prospective study. Gastrointest Endosc 2003; 57: 178-182

21 Prat F, Chapat O, Ducot B, Ponchon T, Pelletier G, Fritsch J, Choury AD, Buffet C. A randomized trial of endoscopic drainage methods for inoperable malignant strictures of the common bile duct. Gastrointest Endosc 1998; 47: 1-7

22 Ortner MA, Liebetruth J, Schreiber S, Hanft M, Wruck U, Fusco V, Muller JM, Hortnagl H, Lochs H. Photodynamic therapy of non resectable cholangiocarcinoma. Gastroenterology 1998; 114: 536-542

23 Dumoulin FL, Gerhardt T, Fuchs S, Scheurlen C, Neubrand M, Layer G, Sauerbruch T. Phase II study of photodynamic therapy and metal stent as palliative treatment for nonresectable hilar cholangiocarcinoma. Gastrointest Endosc 2003; 57: 860-867

24 Ortner ME, Caca K, Berr F, Liebetruh J, Mansmann U, Huster D, Voderholzer W, Schachschal G, Mösner J, Lochs H. Successful Photodynamic Therapy for Nonresectable Cholangiocarcinoma: A Randomized Prospective Study. Gastroenterology 2003; 125: 1535-1536

25 Gores GJ. A spotlight on cholangiocarcinoma. Gastroenterology 2003; 125: 1536-1538

26 Penz M, Korner GV, Raderer M, Ulrich-Pur H, Fiebiger W, Lenaer A, Depisch D, Krauss G, Schneeweiss B, Scheithauer W. Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol 2001; 12: 183-186

27 Raderer M, Hejna MH, Valencak JB, Korner GV, Weinlander GS, Bareck E, Lenaer J, Brodowicz T, Lang F, Scheithauer W. Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer. Oncology 1999; 56: 177-180

28 Schleicher UM, Staatz G, Alzen G, Andreopoulos D. Combined external beam and intraluminal radiotherapy for irresectable Klatskin tumors. Strahlenther Onkol 2002; 178: 682-687

29 Todoroki T, Ohara K, Kawamoto T, Koike N, Yoshida S, Kashihagi H, Otsuka M, Fukao K. Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma. Int J Radiat Oncol Biol Phys 2000; 46: 581-587

30 Haedinger U, Thiele W, Wulf J. Extracranial stereotactic radiotherapy: Evaluation of PTV coverage and dose conformity. Z Med Phys 2002; 12: 221-229

Science Editor Wang XL and Guo SY Language Editor Elsevier HK